BLLN
NASD BillionToOne, Inc. Class A$105.90 ↑ +0.00 (+0.00%) Trading Up from the previous close of $105.90, $3.48 below the day’s high of $109.38
- YTD change
- +29.40%
- vs 20-day SMA
- -1.68%
- vs 200-day SMA
- +11.30%
Price ranges
Price & Performance
+20.40 (+23.86%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 29.6% away from all-time highs of $150.44
- BLLN is up 29% since the beginning of the year
- BLLN is down 3% over the past 12 months
- BLLN is up 10% over the past 1 month
- 11% of all BLLN investors are betting against BLLN
BLLN reads not so good: price sits above one of the two key moving averages, the 12-month move is -2.8%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -15.21%
- vs 8-day SMA
- -8.96%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. Its patented Quantitative Counting Templates (QCT) molecular counting platform is a multiplex technology capable of accurately counting DNA molecules at the single-molecule level. The was founded by Oguzhan Atay, Sukrit Silas, and David Tsao in 2016 and is headquartered in Menlo Park, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.